To estimate utility values associated with CML-CP health states among members of the general public in the UK. METHODS: Interviewer-administered time trade-off utilities were elicited for four CML-CP health states related to risk of progression, from a random sample of 241 members of the general public from eight cities across the UK, using health-state descriptions validated by clinicians and members of the general public. Mean utility values with 95% confi dence intervals (CI) were calculated for each health state. RESULTS: The respondents' mean age was 45 years and 51% were female. Seven percent (n = 18) of respondents had a cancer at the time of the interview which had been diagnosed for a mean 7.0 ± 6.5 years. The mean utilities with 95% CI were: 0.72 (0.69; 0.75) for untreated chronic phase CML, 0.80 (0.79; 0.82) for hematologic response, 0.89 (0.87; 0.90) for cytogenetic response, and 0.94 (0.94; 0.95) for molecular response. The utility values for each state are signifi cantly different from one another (P < 0.001). The respondents' preference values for any of the states were not signifi cantly affected by their demographics or whether they had cancer. Nevertheless, the values elicited from respondents with cancer were lower than those elicited from respondents who did not have cancer: 0.65 versus 0.73 for chronic phase CML; 0.72 versus 0.81 for hematologic response; 0.83 versus 0.89 for cytogenetic response; and 0.89 versus 0.95 for molecular response. CONCLUSIONS: The health states with poorer outcome (e.g., hematologic response) were associated with a lower preference value than the state with the best outcome (i.e., molecular response). The data demonstrate the impact that different treatment responses may have on the health-related quality of life of patients with chronic phase CML and can be used to estimate the outcomes of interventions in terms of quality-adjusted life-years. Ritsumeikan University, Kusatsu, Shiga, Japan; 2 The University of Tokyo, Tokyo, Japan; 3 Japan Clinical Research Support Unit, Tokyo, Japan; 4 Hamamatsu Oncology Center, Hamamatsu, Shizuoka, Japan OBJECTIVES: We investigated the effect of adjuvant chemotherapy regimens on utility scores assessed by the EQ-5D instrument in a randomized controlled trial for breast cancer patients after surgery. METHODS: In the National Surgical Adjuvant Study of Breast Cancer-02 (N-SAS BC 02), 1060 patients were randomly assigned to the following four chemotherapy groups: 1) four cycles of anthracycline (ADM 60 mg/m 2 or EPR 75 mg/m 2 + CPM 600 mg/m 2 , q3 wks x 4) followed by paclitaxel (175 mg/m 2 , q3 wks x 4) (ACP); 2) four cycles of anthracycline followed by docetaxel (75 mg/m 2 q3, wks x 4) (ACD); 3) eight cycles of paclitaxel (175 mg/m 2 , q3 wks x 8) (PTX); and 4) eight cycles of docetaxel (75 mg/m 2 , q3 wks x 8). The fi rst consecutively registered 300 women were the subjects of the present utility study. Utility scores were assessed using the EQ-5D instrument at baseline, 3rd cycle, 5th cycle, 7th cycle, 7 months, and 1 year. The obtained data were analyzed using a linear mixed model with baseline, time, group, and interaction between time and group as explanatory variables. RESULTS: Missing data was observed between 1.9 and 6.1% of cases depending on the time of measurement. The utility score was signifi cantly lower in the DTX group than in the ACP and ACD groups. In the DTX group, the mean utility score was lowest at 7 months, and it tended to remain low for a long time. In a comparison of the anthracycline and taxane groups, the anthracycline group had signifi cantly higher utility scores. There were no signifi cant differences depending on the type of taxane. The estimated mean utility scores were 0.81, 0.83, 0.79, and 0.76 (ACP, ACD, PTX, and DTX group). CONCLUSIONS: The results of this study will be benefi cial not only for clinical decision-making but also for appropriate allocation of medical resources.
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PCN120 UTILITY AND WORK PRODUCTIVITY DATA FOR ECONOMIC EVALUATION OF BREAST CANCER THERAPIES IN THE NETHERLANDS AND SWEDEN
Lloyd A 1 , Quadri N 1 , Tamminga H 2 , Hövels A 2 1 Oxford Outcomes Ltd., Oxford, UK; 2 GlaxoSmithKline B.V, Zeist, The Netherlands OBJECTIVES: Survival and quality of life (utility) are often the main measure of benefi t used in an economic evaluation. Additionally, some decision-makers will consider benefi ts in terms of work productivity. The present study was designed to estimate utilities and productivity loss for women with metastatic breast cancer (MBC) which is Human Epidermal Growth Factor Receptor 2 positive (HER 2+). METHODS: Health-state vignettes describing MBC progressive disease, stable disease, and seven grade 3/4 adverse events (diarrhea, fatigue, anemia, leukopenia, anorexia, decreases in left ventricular ejection fraction [LVEF] , and skin rash) were developed based on interviews with women with MBC in the The Netherlands and Sweden and clinicians. a general public sample rated the states (100 men and women in NL; 100 women aged 50+ in Sweden) using the time trade off method. Women (161 The Netherlands, 52 Sweden) who were currently or recently treated for MBC were surveyed using the Work Productivity and Activity Impairment scale regarding the impact of disease on their ability to work. RESULTS: MBC progressive disease and stable disease were rated more highly in Sweden (0.61, 0.81) than the The Netherlands (0.50, 0.69). Utilities for toxicities ranged from 0.52 to 0.69 (Sweden), and 0.47 to 0.66 (NL). The productivity survey identifi ed that women currently receiving treatment reported that their overall productivity was reduced by 69% (NL) and 72% (Sweden); while those who had recently completed therapy reported reductions of 41% (NL) and 40% (Sweden). CONCLUSIONS: This study captured utility and productivity data for the The Netherlands and Sweden regarding the impact of HER 2+ MBC. Important differences in utilities emerged in the study which could impact cost-effectiveness estimates. The productivity survey demonstrated how the negative impact of breast cancer on productivity persists after women have completed their treatment.
PCN121 CONFIRMATION OF BRIEF PAIN INVENTORY SHORT FORM (BPI-SF) "WORST PAIN" ITEM CUT-POINT FOR THE ASSESSMENT OF PAIN PROGRESSION IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Regnault A 1 , Gater A 2 , Battersby C 3 , Meunier J 1 , Abetz L 2 1 Mapi Values, Lyon, France; 2 Mapi Values Ltd, Bollington, Cheshire, UK; 3 AstraZeneca R&D Alderley Park, Macclesfi eld, England, UK OBJECTIVES: Previous studies in cancer patients have found scores of ≥5 on 11-point pain scales to indicate pain that has a signifi cant impact on patients' lives. This study sought to confi rm the adequacy of a ≥5 cutpoint on the BPI-SF "worst pain" item for defi ning pain progression in CRPC patients using data collected as part of a multinational phase III clinical trial. METHODS: Patients with a BPI-SF worst pain score ≥5 were compared with patients with a score <5 in terms of Functional Assessment of Cancer Therapy-Prostate (FACT-P) subscales and total score and EQ-5D item scores. Exploratory analyses were also conducted to investigate any potential differences within designated regional subgroups of patients. All analyses were performed using treatment-blinded data collected at the fi rst post-baseline trial visit including the above assessments (Week 12). RESULTS: A total of 464 patients completed the BPI-SF at W12 (<5 n = 411, ≥5 n = 53). Mean FACT-P total scores for patients with a BPI-SF worst pain score ≥5 were 24.5 points lower than for patients with a score <5 (91.1 vs. 115.6, P < 0.0001), indicating poorer well-being. Patients with BPI-SF worst pain scores ≥5 consistently had lower scores for all FACT-P subscales (P < 0.0001) except for social well-being. The magnitude of these differences, for all scales, was considerably greater than reported thresholds for meaningful difference. Results for EQ-5D item scores were in a similar direction with signifi cantly greater impairment reported in patients with a BPI-SF worst pain score ≥5 compared with patients with a score <5 (P < 0.0001). Exploratory analyses also revealed similar results across all regional subgroups of patients. CONCLUSIONS: Patient scores ≥5 on the BPI-SF "worst pain" item are associated with signifi cant and meaningful impairments in CRPC patients, thus supporting the adequacy of this cutpoint as an appropriate defi nition of pain progression in this population. The standard lexicon for reporting adverse events in National Cancer Institute (NCI) sponsored clinical trials is the Common Terminology Criteria for Adverse Events (CTCAE), which consists of 790 individual items. Currently, all adverse events are reported by clinicians. However, multiple studies have found that clinicians tend to underreport symptom severity and onset compared with patient self-reports. In 2008, the NCI contracted a multi-institution consortium to develop patient versions of CTCAE items and an electronic platform for capturing symptoms from patients and reporting data to health care providers and researchers. METHODS: A committee including clinical investigators, methodologists, patients, and representatives of NCI and FDA systematically identifi ed CTCAE items with a subjective component amenable to patient reporting. Systematic review and analyses of publications and existing symptom survey data sets and questionnaires were conducted to determine optimal formats for questions, response options, and terms for new PRO-CTCAE items. RESULTS: 81 symptoms were identifi ed in the CTCAE to be amenable to patient reporting. The format and content of these items were found to be inappropri-
PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

